AR and neoplasm: TST-D was shown to reduce AR-V7 mRNA and protein levels (at 5 nM concentration) by disrupting the U2AF65/SAP155 splicing complex that is critical for the AR-V7 pre-mRNA expression and suppressed CRPC cell-derived xenograft tumor growth (50% inhibition at 0.3 mg/kg/day after four days) (50).